2. NCCN Guidelines Version 2. 2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 3. Sharman, Jeff P., et al. "Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive ...
参考文献 [1] Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Annals of Oncology, 2021, 32(1): 23-33. [2] ...
我们应当积极借鉴国外研究的成果,探索我国CLL患者的特点,提高我国CLL的诊治水平。 1.Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer ...
A.2; Paik, J.2; Shadman, M.11,12. P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL. HemaSphere
[5]Hallek M, Cheson BD, Catovsky D,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PMID: 29540348. ...
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
daily on days 1-5 CAP cyclophosphamide 750 mg/m2 daily on day 1 doxorubicin 50 mg/m2 daily on day 1 prednisone 40 mg/m2 daily on days 1-5 Treatment was repeated for a maximum of 6 cycles The French Cooperative Group on CLL et al. Lancet 1996;347:1432-8 年龄18岁 初治CLL Binet ...
Treatment recommendations for patients with del (17p)Although these patients have a poor prognosis and there is no clear standard of care, the National Comprehensive Cancer Network (NCCN) guidelines list the following as preferred regimens for first-line treatment [12] :...
A.2; Paik, J.2; Shadman, M.11,12. P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL. HemaSphere 6():p 560-561, June 2022. | DOI: 10.1097/01.HS9.0000845532.14560...
[9] Annals of Oncology, Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, January 6, 2020.[10] Cerhan, J.R. and T.M. Habermann, Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma, 2021.[11] Smith, A., et al., Lymphoma incidence, ...